Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 1/20 | 0.57 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 7/20 | 0.53 |
| ▸ | REN | P00797 | 1/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051725 | 0.93 | EDNRA (0.60) | EDNRAMAGI3ECE1ERAP2MMP2 | |
| SCHEMBL30262171 | 0.91 | MAGI3 (0.60) | EDNRAMAGI3ERAP2CTSBCTSK | |
| SCHEMBL31098013 | 0.90 | EDNRA (0.61) | EDNRAMAGI3RENERAP2CTSB | |
| SCHEMBL30093406 | 0.89 | EDNRA (0.57) | EDNRAMAGI3ECE1ERAP2CTSB | |
| SCHEMBL30050958 | 0.89 | ECE1 (0.63) | ECE1ERAP2MMP2MMP9MMP8 | |
| SCHEMBL30051687 | 0.88 | ECE1 (0.65) | EDNRAECE1ERAP2KMT2AL3MBTL1 | |
| SCHEMBL31357968 | 0.88 | MAGI3 (0.63) | EDNRAMAGI3ECE1ERAP2MMP2 | |
| SCHEMBL30092892 | 0.88 | EDNRA (0.68) | EDNRAMAGI3ECE1ERAP2CTSB | |
| SCHEMBL30092989 | 0.88 | EDNRA (0.68) | EDNRAMAGI3ECE1ERAP2CTSB | |
| SCHEMBL30680479 | 0.88 | ERAP2 (0.62) | EDNRAMAGI3ECE1ERAP2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612439-B2 | Mutant bacteriorhodopsin-like-channelrhodopsin ion channel | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) | 2026-04-28 | — | — | US | disclosed |
| US-20230250143-A1 | NOVEL MUTANT BACTERIORHODOPSIN-LIKE-CHANNELRHODOPSIN ION CHANNEL | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612439-B2 | Mutant bacteriorhodopsin-like-channelrhodopsin ion channel | TRPC1, TRPC6, TRPC4 | EDNRA 1660/4885MAGI3 4014/4885ECE1 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.